Study of a targeted drug for recurrent uterine cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new drug called TUB-040 for uterine cancer that has come back or not responded to previous treatments. The drug targets a protein on cancer cells and delivers a chemotherapy directly to them. This might help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of uterine cancer called serous or endometrioid (or a mix where one of these is the main type).
- You've had at least one line of chemotherapy that included a platinum drug, and also at least one line of immunotherapy (PD-1 or PD-L1 inhibitor).
- Your cancer has grown or come back after your most recent treatment.
- You are 18 years or older and able to care for yourself (ECOG 0 or 1).
- You have a tumor sample that can be tested, or you're willing to have a new biopsy.
- Your overall health is good enough, with normal liver, kidney, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial is testing an experimental therapy against standard chemotherapy for people with endometrial cancer that has come back. The study looks for a certain protein (HER2) on cancer cells to decide which treatment group you may be in.
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
This study tests a new drug called TUB-040 that targets a protein (NaPi2b) found on some ovarian and lung cancer cells. It is for people whose cancer has stopped responding to standard treatments and who have not had certain lung problems in the past.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
Hear when a new Uterine Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.